Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jenna D Goldberg

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
Clinical and Translational Science|December 24, 2022
First-in-human study of JNJ-63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemiaMichael Boyiadzis, Pinkal Desai, Nikki Daskalakis, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 10, 2013
A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patientsCraig S Sauter, Juliet N Barker, Lauren Lechner, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 19, 2013
A novel reduced-intensity conditioning regimen induces a high incidence of sustained donor-derived neutrophil and platelet engraftment after double-unit cord blood transplantationDoris M Ponce, Craig Sauter, Sean Devlin, et al.
Leukemia & Lymphoma|December 6, 2011
Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplantJenna D Goldberg, Joanne F Chou, Steven Horwitz, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 24, 2014
Assessment of joint and fascia manifestations in chronic graft-versus-host diseaseYoshihiro Inamoto, Joseph Pidala, Xiaoyu Chai, et al.
Blood|September 27, 2012
Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantationMiguel-Angel Perales, Jenna D Goldberg, Jianda Yuan, et al.
Targeted Oncology|June 24, 2022
Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple MyelomaSuzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, et al.
Targeted Oncology|August 1, 2022
Correction: Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple MyelomaSuzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, et al.
Leukemia & Lymphoma|May 31, 2017
Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimusGeorg Hess, Simon Rule, Wojciech Jurczak, et al.
Leukemia & Lymphoma|January 12, 2017
Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplantJenna D Goldberg, Junting Zheng, Ravin Ratan, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Clinical and Translational Science|December 24, 2022
First-in-human study of JNJ-63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemiaMichael Boyiadzis, Pinkal Desai, Nikki Daskalakis, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 10, 2013
A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patientsCraig S Sauter, Juliet N Barker, Lauren Lechner, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 19, 2013
A novel reduced-intensity conditioning regimen induces a high incidence of sustained donor-derived neutrophil and platelet engraftment after double-unit cord blood transplantationDoris M Ponce, Craig Sauter, Sean Devlin, et al.
Leukemia & Lymphoma|December 6, 2011
Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplantJenna D Goldberg, Joanne F Chou, Steven Horwitz, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 24, 2014
Assessment of joint and fascia manifestations in chronic graft-versus-host diseaseYoshihiro Inamoto, Joseph Pidala, Xiaoyu Chai, et al.
Blood|September 27, 2012
Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantationMiguel-Angel Perales, Jenna D Goldberg, Jianda Yuan, et al.
Targeted Oncology|June 24, 2022
Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple MyelomaSuzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, et al.
Targeted Oncology|August 1, 2022
Correction: Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple MyelomaSuzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, et al.
Leukemia & Lymphoma|May 31, 2017
Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimusGeorg Hess, Simon Rule, Wojciech Jurczak, et al.
Leukemia & Lymphoma|January 12, 2017
Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplantJenna D Goldberg, Junting Zheng, Ravin Ratan, et al.
Pageof 4